The Latest Breaking News from Moderna

FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’

Experts say ‘they’re just coming up with reasons’ as agency says application lacked ‘adequate and well controlled’ trial

The Guardian - US · Feb 13

Clinical Trials Show Moderna's New mRNA Flu Vaccine Is Safe and Effective. FDA Won't Even Consider It.

An overzealous government agency suppresses medical innovation yet again.

Reason · Feb 12

FDA rejects Moderna’s mRNA flu vaccine application - for reasons with no basis in the law

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its mRNA-based flu vaccine.

The Conversation · Feb 12

How To Speed Up the Search for Cures Through a Change in Probability Theory

It seems likely the FDA would do well to accept more Bayesian reasoning in medical research.

Reason · Feb 3

Are Wall Street Analysts Bullish on Moderna Stock?

While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Barchart · Feb 3

3 ETFs Catapulting Beyond the S&P to Start the Year

Three ETFs with year-to-date performance of 30% or better include a fund focused on drone technology, one targeting nickel miners, and a covered call play.

MarketBeat · Jan 29

Promising vaccine for aggressive melanoma could unlock the body’s potential to fight cancer

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

Euronews · Jan 21

Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?

COVID-19 vaccine stock Moderna just got its biggest lift in recent memory, moving up 17%. Can MRNA stage a broader recovery, down +90% from its all-time high?

MarketBeat · Jan 20

New personalized skin cancer treatment shows success in preventing return of high-risk melanoma

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, pharmaceutical companies Moderna and Merck announced in five-year findings.

The Independent UK · Jan 20

Life-saving therapies are being delayed as research funding dries up

Letter: Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts

The Guardian - UK · Jan 9